Mast cells are immune cells found in tissues throughout the body that play an important role in allergic reactions and modulating the immune response. They respond to triggers like pathogens, allergens, and physiological stress by releasing chemical mediators that cause inflammation. Under normal conditions, mast cell responses are regulated by endogenous fatty acid amides through a negative feedback loop. However, during persistent physiological stress this regulation can fail, leading to uncontrolled mast cell degranulation and potential tissue damage. Adelmidrol is a fatty acid amide analogue that acts through the same regulatory mechanism to control mast cell responses and restore homeostasis during periods of stress.
This is a high level view of aspects of sales and marketing for hospitals. There would be variations and details based on the actual hospital, specialties, service area demographic etc.
The document discusses the Indian healthcare sector. It notes that healthcare is one of India's largest sectors in terms of revenue and employment. The private sector accounts for over 80% of healthcare spending. The sector is projected to grow to $40 billion this year. An aging population and expanding middle class represent opportunities for growth. However, physical infrastructure and the number of public health facilities are inadequate. The government uses price controls to improve drug affordability. [END SUMMARY]
The slide is all about Healthcare Marketing. How you can develop marketing strategies in healthcare market.
Healthcare is booming industry & in accordance with marketing concepts it is very necessary to do marketing of services.
This document summarizes dermatological pharmacology. It discusses the structure of skin and topical vehicles like creams, lotions, gels and ointments used to deliver drugs to the skin. It also discusses various drug classes used in dermatology like glucocorticoids, retinoids, antibiotics, antifungals and immunomodulators. Specific drugs covered include tretinoin, adapalene, isotretinoin, calcipotriene and phototherapy agents. It also provides information on treatment of conditions like acne, hyperpigmentation and photoprotection with sunscreens.
This document discusses dermal toxicity and its effects on the skin. It begins by defining dermal toxicity as the ability of substances to poison through skin contact. It then describes the three main layers of skin - the epidermis, dermis and hypodermis - and their functions. Various manifestations of dermal toxicity are outlined, including contact dermatitis, ulcers, pigment disturbances and skin cancer. Specific toxic chemicals that can cause these effects are also mentioned.
Drug eruptions can mimic various skin conditions and are often caused by medications. The document defines adverse drug reactions and lists common inducing drugs. It describes several types of drug eruptions like maculopapular eruptions, urticaria, angioedema, DRESS syndrome, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, fixed drug eruptions, leukocytoclastic vasculitis, photosensitivity, erythroderma, erythema nodosum, acute generalized exanthematous pustulosis, and anticoagulant skin necrosis. It emphasizes the importance of history, physical exam, potential lab tests, identifying the culprit drug
This is a high level view of aspects of sales and marketing for hospitals. There would be variations and details based on the actual hospital, specialties, service area demographic etc.
The document discusses the Indian healthcare sector. It notes that healthcare is one of India's largest sectors in terms of revenue and employment. The private sector accounts for over 80% of healthcare spending. The sector is projected to grow to $40 billion this year. An aging population and expanding middle class represent opportunities for growth. However, physical infrastructure and the number of public health facilities are inadequate. The government uses price controls to improve drug affordability. [END SUMMARY]
The slide is all about Healthcare Marketing. How you can develop marketing strategies in healthcare market.
Healthcare is booming industry & in accordance with marketing concepts it is very necessary to do marketing of services.
This document summarizes dermatological pharmacology. It discusses the structure of skin and topical vehicles like creams, lotions, gels and ointments used to deliver drugs to the skin. It also discusses various drug classes used in dermatology like glucocorticoids, retinoids, antibiotics, antifungals and immunomodulators. Specific drugs covered include tretinoin, adapalene, isotretinoin, calcipotriene and phototherapy agents. It also provides information on treatment of conditions like acne, hyperpigmentation and photoprotection with sunscreens.
This document discusses dermal toxicity and its effects on the skin. It begins by defining dermal toxicity as the ability of substances to poison through skin contact. It then describes the three main layers of skin - the epidermis, dermis and hypodermis - and their functions. Various manifestations of dermal toxicity are outlined, including contact dermatitis, ulcers, pigment disturbances and skin cancer. Specific toxic chemicals that can cause these effects are also mentioned.
Drug eruptions can mimic various skin conditions and are often caused by medications. The document defines adverse drug reactions and lists common inducing drugs. It describes several types of drug eruptions like maculopapular eruptions, urticaria, angioedema, DRESS syndrome, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, fixed drug eruptions, leukocytoclastic vasculitis, photosensitivity, erythroderma, erythema nodosum, acute generalized exanthematous pustulosis, and anticoagulant skin necrosis. It emphasizes the importance of history, physical exam, potential lab tests, identifying the culprit drug
This document summarizes skin toxicology. It discusses the structure and functions of the skin, percutaneous absorption, and various skin diseases and conditions including occupational skin diseases, contact dermatitis, phototoxicity, granulomatous disease, acne, pigmentary disturbances, urticaria, toxic epidermal necrolysis, and skin cancer. It provides details on the causes, mechanisms, and characteristics of these diseases and conditions.
This document discusses muscle weakness and skin rash (dermatomyositis). It provides information on the clinical presentation, causes, diagnostic criteria and classification, investigations, histopathological findings, treatment and prognosis of dermatomyositis. Key points include that dermatomyositis involves proximal muscle weakness and a skin rash. Diagnosis involves elevated muscle enzymes, electromyography, muscle biopsy and the presence of a skin rash. Treatment primarily involves oral steroids. Prognosis depends on factors like age, presence of malignancy and disease recalcitrance.
This document provides an overview of vitiligo, including its definition, epidemiology, etiology, classification, clinical manifestations, pathogenesis, diagnosis, and treatment. Some key points are:
- Vitiligo is a skin condition characterized by loss of pigment-producing cells that results in white patches on the skin. It affects around 0.5-1% of the population worldwide.
- The precise causes are unknown but are believed to involve genetic and environmental factors that may trigger an autoimmune response targeting melanocytes.
- Vitiligo can be classified based on the distribution of lesions as segmental, non-segmental, generalized, or other subtypes.
- Treatment options include phototherapy, topical
The document summarizes various drugs used for their anti-inflammatory and immunosuppressive properties. It discusses how immunosuppressants like cyclosporine, tacrolimus, and sirolimus inhibit T-cell activation and proliferation to prevent transplant rejection and treat autoimmune disorders. Newer biologic drugs targeting TNF are also mentioned. For gout, acute attacks are treated with anti-inflammatory drugs while prevention involves colchicine and allopurinol to decrease uric acid production or probenecid to increase uric acid excretion.
learning objectives : Pathophysiology of Psoriasis
Common sites with pictures
Pharmacotherapy of Psoriasis
Local Drug therapy
Systemic Drug therapy
Biological therapy
Phototherapy
Cellulitis is an acute bacterial skin infection that causes skin inflammation and swelling. It is usually caused by Streptococcus pyogenes or Staphylococcus aureus entering through a break in the skin. Risk factors include skin injuries, conditions like eczema, obesity, and diabetes. Signs include redness, pain, swelling and warmth in the infected area. Treatment involves antibiotics, wound care, elevation and rest. Complications can include tissue damage, gangrene and sepsis if not properly treated.
This document discusses histamine, an amine that acts as a chemical messenger in many cellular responses. It is released from mast cells and basophils during allergic reactions and causes symptoms like congestion and itching. Antihistamines block the H1 receptor to reduce these symptoms. H2 blockers inhibit gastric acid secretion by blocking the H2 receptor. Research continues on the roles and potential drug targets of other histamine receptors like H3, H4, and ligands that may treat conditions like sleep disorders, pruritus, and autoimmune disease.
This document summarizes different types of anti-allergic remedies. It describes two types of allergic reactions: immediate hypersensitivity reactions and delayed hypersensitivity reactions. It then classifies anti-allergic remedies into those used for immediate reactions and those for delayed reactions. Examples are provided of remedies that prevent mast cell degranulation like cromoglycic acid, ketotifen, and nedocromil. Antihistamines that block H1 receptors like diphenhydramine and loratadine are also discussed. Glucocorticoids, cytostatics, and other immunosuppressants used to treat allergies are outlined.
This document discusses dermatologic pharmacology. It covers topics like variables affecting pharmacologic response, percutaneous absorption, skin as a pharmacological target, dermatologic formulations, adverse effects of preparations, topical antibacterial, antifungal, antiviral agents, immunomodulators, ectoparasiticides, agents affecting pigmentation, sunscreens, and preparations for acne, psoriasis and other inflammatory dermatologic conditions. It provides details on various active ingredients and how they work.
This document discusses dermatologic pharmacology. It covers topics like variables affecting pharmacologic response, percutaneous absorption, skin as a pharmacological target, dermatologic formulations, adverse effects of preparations, topical antibacterial, antifungal, antiviral agents, immunomodulators, ectoparasiticides, agents affecting pigmentation, sunscreens, and preparations for acne, psoriasis and other inflammatory dermatologic conditions. It provides details on various active ingredients and how they work.
IN VIVO MODELS FOR EVALUATION OF ANTI INFLAMMATORY DRUGSAnushma Chorsiya
This document describes various in vivo models used to evaluate anti-inflammatory drugs and activity. It discusses factors that cause inflammation and the two main types: acute and chronic. Several animal models are described in detail, including carrageenan-induced paw edema in rats, cotton pellet-induced granuloma, croton oil ear edema, and oxazolone-induced ear edema. Evaluation methods for each model involving measurement of edema, granuloma, erythema, and cytokine levels are provided. The document concludes with references used in the study of anti-inflammatory properties of plant extracts in these standard in vivo models.
This document discusses anaphylaxis and anaphylactoid reactions. It defines anaphylaxis as a severe, immediate hypersensitivity reaction involving multiple organ systems. Anaphylactoid reactions present similarly but are non-immune mediated. The document outlines the pathophysiology of type 1 hypersensitivity reactions and mast cell degranulation in anaphylaxis. Clinical presentations range from mild to life-threatening depending on the organ systems involved. Perioperative anaphylaxis risk factors and common causal agents are identified. Treatment focuses on epinephrine administration, airway support, IV fluids and adjunctive therapies.
Psoriasis is a chronic, inflammatory skin condition characterized by thickened patches of red skin covered by silvery scales. It occurs when the immune system causes skin cells to grow too quickly. The document defines psoriasis and describes the main types, risk factors, diagnosis, and treatment options including topical therapies, phototherapy, and systemic medications that target the immune system. Treatment aims to reduce inflammation and scaling based on the severity and location of symptoms.
This document discusses common dermatological side effects from cancer treatments like chemotherapy and radiation therapy. It provides information on managing common skin issues such as dry skin, itchy skin, hyperpigmentation, photosensitivity, radiation recall rash, pressure sores, sweating, acne-like eruptions, and nail changes. Specific drugs that can cause each side effect are identified. General skin care recommendations during cancer treatment focus on moisturizing to prevent dry skin, protecting from sun exposure, and treating infected nails.
Mometasone furoate 0.1% w/w cream is used to treat plaque psoriasis, atopic eczema, allergic dermatitis, and seborrheic dermatitis. It works by inhibiting inflammatory mediators like prostaglandins and reducing swelling, itching, and redness. Mometasone furoate has minimal systemic absorption and is generally well-tolerated, though long term use or use on sensitive areas can cause skin thinning and irritation in some patients. It should be used with caution in pediatric patients, pregnant/nursing women, and those with viral skin infections or rosacea.
This document provides information about group members studying psoriasis and summarizes key points about the disease. It discusses the etiology, pathogenesis, clinical manifestations, types, diagnosis and first-line and second-line treatment options for psoriasis. Psoriasis is characterized by thickened, scaly skin plaques and is caused by an immune system problem involving T cells. Common types include plaque, guttate and pustular psoriasis. Treatment involves topical corticosteroids, vitamin D analogs and systemic drugs like methotrexate, cyclosporine and biologics that target T cells and inflammation.
Adverse drug reaction of drugs used in skin. Sudipta Roy
Abstract:
Cutaneous adverse reactions may be dangerous from transitory exanthematous rash ( It is the most frequent of all cutaneous reactions to drugs and may occur with almost any drug at any time upto three weeks (but usually two) after administration) to the potentially fatal Toxic Epidermal Necrolysis (TEN). An adverse reaction is noxious and unintentionally occurs at dosages normally used in people for prophylaxis, diagnosis or therapy of disease or for the modification of physiological function. Here in this poster presentation various types of cutaneous drug reaction will be presenting on basis of theoretical aspect and already experimented data to create awareness of cutaneous drug reactions and some basic concept of drug allergy, mechanism of drug absorption through skin layers to clear concept of over dose associated with right dosage regimen of pharmaceutically prepared chemically synthesized and herbal formulation.
This document summarizes skin toxicology. It discusses the structure and functions of the skin, percutaneous absorption, and various skin diseases and conditions including occupational skin diseases, contact dermatitis, phototoxicity, granulomatous disease, acne, pigmentary disturbances, urticaria, toxic epidermal necrolysis, and skin cancer. It provides details on the causes, mechanisms, and characteristics of these diseases and conditions.
This document discusses muscle weakness and skin rash (dermatomyositis). It provides information on the clinical presentation, causes, diagnostic criteria and classification, investigations, histopathological findings, treatment and prognosis of dermatomyositis. Key points include that dermatomyositis involves proximal muscle weakness and a skin rash. Diagnosis involves elevated muscle enzymes, electromyography, muscle biopsy and the presence of a skin rash. Treatment primarily involves oral steroids. Prognosis depends on factors like age, presence of malignancy and disease recalcitrance.
This document provides an overview of vitiligo, including its definition, epidemiology, etiology, classification, clinical manifestations, pathogenesis, diagnosis, and treatment. Some key points are:
- Vitiligo is a skin condition characterized by loss of pigment-producing cells that results in white patches on the skin. It affects around 0.5-1% of the population worldwide.
- The precise causes are unknown but are believed to involve genetic and environmental factors that may trigger an autoimmune response targeting melanocytes.
- Vitiligo can be classified based on the distribution of lesions as segmental, non-segmental, generalized, or other subtypes.
- Treatment options include phototherapy, topical
The document summarizes various drugs used for their anti-inflammatory and immunosuppressive properties. It discusses how immunosuppressants like cyclosporine, tacrolimus, and sirolimus inhibit T-cell activation and proliferation to prevent transplant rejection and treat autoimmune disorders. Newer biologic drugs targeting TNF are also mentioned. For gout, acute attacks are treated with anti-inflammatory drugs while prevention involves colchicine and allopurinol to decrease uric acid production or probenecid to increase uric acid excretion.
learning objectives : Pathophysiology of Psoriasis
Common sites with pictures
Pharmacotherapy of Psoriasis
Local Drug therapy
Systemic Drug therapy
Biological therapy
Phototherapy
Cellulitis is an acute bacterial skin infection that causes skin inflammation and swelling. It is usually caused by Streptococcus pyogenes or Staphylococcus aureus entering through a break in the skin. Risk factors include skin injuries, conditions like eczema, obesity, and diabetes. Signs include redness, pain, swelling and warmth in the infected area. Treatment involves antibiotics, wound care, elevation and rest. Complications can include tissue damage, gangrene and sepsis if not properly treated.
This document discusses histamine, an amine that acts as a chemical messenger in many cellular responses. It is released from mast cells and basophils during allergic reactions and causes symptoms like congestion and itching. Antihistamines block the H1 receptor to reduce these symptoms. H2 blockers inhibit gastric acid secretion by blocking the H2 receptor. Research continues on the roles and potential drug targets of other histamine receptors like H3, H4, and ligands that may treat conditions like sleep disorders, pruritus, and autoimmune disease.
This document summarizes different types of anti-allergic remedies. It describes two types of allergic reactions: immediate hypersensitivity reactions and delayed hypersensitivity reactions. It then classifies anti-allergic remedies into those used for immediate reactions and those for delayed reactions. Examples are provided of remedies that prevent mast cell degranulation like cromoglycic acid, ketotifen, and nedocromil. Antihistamines that block H1 receptors like diphenhydramine and loratadine are also discussed. Glucocorticoids, cytostatics, and other immunosuppressants used to treat allergies are outlined.
This document discusses dermatologic pharmacology. It covers topics like variables affecting pharmacologic response, percutaneous absorption, skin as a pharmacological target, dermatologic formulations, adverse effects of preparations, topical antibacterial, antifungal, antiviral agents, immunomodulators, ectoparasiticides, agents affecting pigmentation, sunscreens, and preparations for acne, psoriasis and other inflammatory dermatologic conditions. It provides details on various active ingredients and how they work.
This document discusses dermatologic pharmacology. It covers topics like variables affecting pharmacologic response, percutaneous absorption, skin as a pharmacological target, dermatologic formulations, adverse effects of preparations, topical antibacterial, antifungal, antiviral agents, immunomodulators, ectoparasiticides, agents affecting pigmentation, sunscreens, and preparations for acne, psoriasis and other inflammatory dermatologic conditions. It provides details on various active ingredients and how they work.
IN VIVO MODELS FOR EVALUATION OF ANTI INFLAMMATORY DRUGSAnushma Chorsiya
This document describes various in vivo models used to evaluate anti-inflammatory drugs and activity. It discusses factors that cause inflammation and the two main types: acute and chronic. Several animal models are described in detail, including carrageenan-induced paw edema in rats, cotton pellet-induced granuloma, croton oil ear edema, and oxazolone-induced ear edema. Evaluation methods for each model involving measurement of edema, granuloma, erythema, and cytokine levels are provided. The document concludes with references used in the study of anti-inflammatory properties of plant extracts in these standard in vivo models.
This document discusses anaphylaxis and anaphylactoid reactions. It defines anaphylaxis as a severe, immediate hypersensitivity reaction involving multiple organ systems. Anaphylactoid reactions present similarly but are non-immune mediated. The document outlines the pathophysiology of type 1 hypersensitivity reactions and mast cell degranulation in anaphylaxis. Clinical presentations range from mild to life-threatening depending on the organ systems involved. Perioperative anaphylaxis risk factors and common causal agents are identified. Treatment focuses on epinephrine administration, airway support, IV fluids and adjunctive therapies.
Psoriasis is a chronic, inflammatory skin condition characterized by thickened patches of red skin covered by silvery scales. It occurs when the immune system causes skin cells to grow too quickly. The document defines psoriasis and describes the main types, risk factors, diagnosis, and treatment options including topical therapies, phototherapy, and systemic medications that target the immune system. Treatment aims to reduce inflammation and scaling based on the severity and location of symptoms.
This document discusses common dermatological side effects from cancer treatments like chemotherapy and radiation therapy. It provides information on managing common skin issues such as dry skin, itchy skin, hyperpigmentation, photosensitivity, radiation recall rash, pressure sores, sweating, acne-like eruptions, and nail changes. Specific drugs that can cause each side effect are identified. General skin care recommendations during cancer treatment focus on moisturizing to prevent dry skin, protecting from sun exposure, and treating infected nails.
Mometasone furoate 0.1% w/w cream is used to treat plaque psoriasis, atopic eczema, allergic dermatitis, and seborrheic dermatitis. It works by inhibiting inflammatory mediators like prostaglandins and reducing swelling, itching, and redness. Mometasone furoate has minimal systemic absorption and is generally well-tolerated, though long term use or use on sensitive areas can cause skin thinning and irritation in some patients. It should be used with caution in pediatric patients, pregnant/nursing women, and those with viral skin infections or rosacea.
This document provides information about group members studying psoriasis and summarizes key points about the disease. It discusses the etiology, pathogenesis, clinical manifestations, types, diagnosis and first-line and second-line treatment options for psoriasis. Psoriasis is characterized by thickened, scaly skin plaques and is caused by an immune system problem involving T cells. Common types include plaque, guttate and pustular psoriasis. Treatment involves topical corticosteroids, vitamin D analogs and systemic drugs like methotrexate, cyclosporine and biologics that target T cells and inflammation.
Adverse drug reaction of drugs used in skin. Sudipta Roy
Abstract:
Cutaneous adverse reactions may be dangerous from transitory exanthematous rash ( It is the most frequent of all cutaneous reactions to drugs and may occur with almost any drug at any time upto three weeks (but usually two) after administration) to the potentially fatal Toxic Epidermal Necrolysis (TEN). An adverse reaction is noxious and unintentionally occurs at dosages normally used in people for prophylaxis, diagnosis or therapy of disease or for the modification of physiological function. Here in this poster presentation various types of cutaneous drug reaction will be presenting on basis of theoretical aspect and already experimented data to create awareness of cutaneous drug reactions and some basic concept of drug allergy, mechanism of drug absorption through skin layers to clear concept of over dose associated with right dosage regimen of pharmaceutically prepared chemically synthesized and herbal formulation.
Similar to Again Life Italia Product Information (20)
2. Mast cells are immune cells which line the surfaces of the body including the skin, the
respiratory, gastro-intestinal and genito-urinary tracts1. They are in a prime position to
recognise and counter foreign antigens, pathogens or toxins1, and play an important role in
the modulation of an appropriate immune response2.
Mast cells respond to a number of triggers including pathogens (bacterial, fungal, viral),
allergens, proteins (cytokines, growth factors and hormones) and other triggers (radioactivity,
drugs, trauma)3.
Mast cells are involved in allergic reactions, during which degranulation leads to release of
chemical mediators including histamine and cytokines4, resulting in an immune response
and inflammation. Mast cells are also able to synthesise and release specific mediators
in response to pathogens and other triggers without degranulation4,5. Mast cells play an
immunomodulatory role, influencing the immune response as a whole (inflammation, tissue
remodelling and wound healing) and specifically the mast cell response1.
Selective and
controlled
degranulation
Normal Stimulation Trigger
Endogenous fatty
acid amides
The mast cell response is regulated at a local level by endogenous chemicals or autocoids,
in particular fatty acid amides, which control the mast cell response via a negative feedback
loop6. This process is known as autocoid local injury antagonism (ALIA)6.
Controlled release of:
Histamine
Serotonin
Proteases
Nerve growth factor (NGF)
Nitrous oxide (NO)
Normal tissue reaction
Interleukin
Tumour necrosis factor- (TNF- )
Vascular endothelial growth factor (VEGF)
Other mediators
3. During persistent physiological stress, the release of chemical mediators from mast cells
can become uncontrolled7. This is due to a lack of endogenous fatty acid amides resulting in
an uncontrolled release of non-specific mediators from hyper-reactive mast cells leading to
inflammation and potential tissue damage8.
Non-selective
and uncontrolled
degranulation
Physiological stress
(radiotherapy, chemotherapy,
Excess stimulation heat, trauma, infection,
hormonal changes)
Uncontrolled release of: De-epithelialisation
Changes in connective tissue
Erythema
Histamine
Oedema/swelling
Serotonin
Erosion
Proteases
Ulcer
NGF
Desquamative changes
NO
Itching
Interleukin
Burning
TNF-
Dryness
VEGF
Pain
Other mediators
Development of chronic disease
Atrophy
Oxidative damage
Loss of resistance/elasticity
Hyperalgesia
4. In order to avoid potential tissue damage resulting from persistent physiological stress, it is
important to regulate the hyper-reactive mast cell and regain homeostasis1.
Adelmidrol is a fatty acid amide analogue which acts via the ALIA mechanism to regulate
mast cell response to stimuli9.
Adelmidrol modulates the mast cell reaction by controlling the release of chemical mediators
and regaining homeostasis10-13.
Selective and
controlled
degranulation
Physiological stress
(radiotherapy, chemotherapy,
Excess stimulation heat, trauma, infection,
hormonal changes)
Adelmidrol
Controlled release of:
Histamine
Serotonin
Proteases
NGF Restoration of a
NO normal tissue reaction
Interleukin
TNF-
VEGF
Other mediators
5. Adelmidrol from AgainLife
For skin problems
DerLife For inflamed, red, desquamated and/or dehydrated skin in patients undergoing
radiation or chemotherapy and in patients with burns, post-septic or post-surgical stress.
milk and cream
30 ml 100 ml
RaLife For skin changes, including itching, irritation and redness, in patients undergoing
radiation or chemotherapy and in patients with burns, post-septic or post-surgical stress.
milk and cream
30 ml 100 ml
ClinLife To combat osmidrosis (foul smelling sweat) and/or bromhidrosis (excessive sweating) in
patients with cancer receiving radiation and/or chemotherapy.
milk and cream
30 ml 100 ml
For muco-genital problems
EvaLife For the treatment of itching, burning, redness and dryness of the vulva and vagina
in patients undergoing radiation or chemotherapy and in patients with burns, post-septic
gel and wash
or post-surgical stress.
30 ml 100 ml
HomoLife For the treatment of itching, burning, redness and dryness of the foreskin and penis in
patients undergoing radiation or chemotherapy, and in patients with burns, post-septic,
gel and wash
post-surgical stress or after instrumental manoeuvres.
30 ml 100 ml
GutLife For the treatment of skin/mucosal changes (itching, burning, redness, swelling and
tenderness) in the anal and peri-anal area in patients undergoing radiation or
ointment
chemotherapy and in patients with burns, post-septic or post-surgical stress.
30 ml
For nail and hair problems
OnicoLife For the treatment of tender and/or fragile nails in patients undergoing radiation or
chemotherapy and in patients with burns, post-septic or post-surgical stress. May also be
drops
useful for onychorrhexis (longnitudinal nail ridges), onychoschizia (split nails), xanthonychia
(yellowed nails), melanonychia (blackened nails) and onychocryptosis (ingrown nails).
15 ml
OnicoLife For the treatment of paronychia (skin infection around the nail) in patients undergoing
radiation or chemotherapy and in patients with burns, post-septic or post-surgical stress.
gel
5 ml
ZerLife For the treatment of changes in hair growth (fragile hair or hair loss) caused by
radiation, chemotherapy or environmental stress.
shampoo and lotion
100 ml 100 ml
For oral mucosa problems
OraLife For the treatment of red, painful, swollen and/or dry oral mucosa in patients undergoing
radiation or chemotherapy and in patients with burns, post-septic or post-surgical stress.
mouthwash and gel
30 ml 100 ml
TraLife For the treatment of the oropharyngeal cavity in patients undergoing radiation or
chemotherapy and in patients with burns, post-septic or post-surgical stress.
spray
30 ml
6. References
1. Galli SJ, Grimbaldeston M, Tsai M. Immunomodulatory mast 8. Re G, Barbero R, Miolo A et al. Palmitoylethanolamide,
cells: negative, as well as positive, regulators of immunity. Nat endocannabinoids and related cannabimimetic compounds
Rev Immunol 2008;8(6):478-486. in protection against tissue inflammation and pain: potential
use in companion animals. Vet J 2007;173(1):21-30.
2. Abraham SN, St John AL. Mast cell-orchestrated immunity to
pathogens. Nat Rev Immunol 2010;10(6):440-452. 9. De Filippis D, D’ mico A, Cinelli MP et al. Adelmidrol, a
A
palmitoylethanolamide analogue, reduces chronic inflammation
3. Moon TC, St Laurent CD, Morris KE et al. Advances in mast in a carrageenin-granuloma model in rats. J Cell Mol Med
cell biology: new understanding of heterogeneity and function. 2009;13(6):1086-1095.
Mucosal Immunol 2010;3(2):111-128.
10. Micali G, Pulvirenti N, Musumeci ML et al. Topical adelmidrol
4. Theoharides TC, Kempuraj D, Tagen M et al. Differential 2% emulsion, a novel aliamide, in the treatment of mild atopic
release of mast cell mediators and the pathogenesis of dermatitis in pediatric subjects: a pilot study. J Am Acad
inflammation. Immunol Rev 2007;217:65-78. Dermatol 2006; 54 (3): Suppl AB112.
5. Galli SJ, Tsai M. Mast cells: versatile regulators of inflammation, 11. Pulvirenti N, Nasca MR, Micali G. Topical adelmidrol 2%
tissue remodeling, host defense and homeostasis. J Dermatol emulsion, a novel aliamide, in the treatment of mild atopic
Sci 2008;49(1):7-19. dermatitis in pediatric subjects: a pilot study. Acta
Dermatovenerol Croat 2007;15(2):80-83.
6. Aloe L, Leon A, Levi-Montalcini R. A proposed autacoid
mechanism controlling mastocyte behaviour. Agents Actions 12. Bonello D, Squarzoni P. Effect of a mucoadhesive gel and
1993;39 Spec No:C145-7. dental scaling on gingivitis in dogs. J Vet Dent 2008;25(1):28-32.
7. Harvima IT, Nilsson G, Naukkarinen A. Role of mast cells and 13. Abramo F, Sailuzzi D, Leotta R et al. Mast cell morphometry
sensory nerves in skin inflammation. G Ital Dermatol Venereol and densitimetry in experimental skin wounds treated with
2010;145(2):195-204. a gel containing adelmidrol: a placebo controlled study.
Wounds 2008;20(6):149-157.
Mosaic Pharma Ltd Telephone Email
Harpenden +44(0)333 6000 166 info@mosaicpharma.com
Hertfordshire
AL5 1QJ Fax Website
United Kingdom +44(0)158 2766 622 www.mosaicpharma.com